Navigation Links
Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
Date:9/17/2007

Loutit Brings Significant Experience in Pulmonary and Infectious Disease

Drug Development

SAN DIEGO, Sept. 17 /PRNewswire/ -- Mpex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing products to overcome issues of antibiotic resistance, today announced the appointment of Dr. Jeffery Loutit as the Company's Chief Medical Officer. Dr. Loutit joins Mpex from InterMune, Inc. where since 2001 he has held positions of increasing responsibility and most recently was Vice President of Clinical Science. At InterMune he led multiple Phase 1-3 clinical trials, including two global Phase 3 trials for pirfenidone in patients with idiopathic pulmonary fibrosis. In addition, he negotiated pivotal trial designs for pirfenidone with US and European regulatory agencies and led the late stage clinical development of the anti-infective compound oritavancin, which was subsequently successfully out-licensed.

Prior to entering industry, Dr. Loutit was Chief of the Infectious Diseases Section, Veterans Administration Health Care System in Palo Alto and Assistant Professor of Medicine, Stanford University Medical School, where he published extensively in the area of infectious disease. He received his medical and microbiology degrees from Otago University in New Zealand and is board certified in the US in both infectious disease and internal medicine.

"We believe Jeff will be a great addition to our senior management," said Daniel Burgess, President & CEO of Mpex Pharmaceuticals. "His distinguished reputation and extensive early and late-stage trial experience will be a perfect complement to our scientific and clinical team as we advance our drug candidates. In particular, his protocol design background in both pulmonary and infectious disease medicine is ideally suited to leading our development efforts for MP-376, an agent being developed for the treatment of chronic respiratory infections in patie
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Wisconsin IT association names Gee president, CEO
4. Quintessence Biosciences names new president
5. CDW names VP to handle Berbee merger
6. NimbleGen names CFO with capital-raising past
7. Cisco names Berbee a top partner of 2005
8. Cisco names Inacom most innovative partner
9. UW-Madison medical school names new dean
10. GE Healthcare names new CEO
11. Bruker AXS names new leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.531 12/2001 , ... , , , , ... , Cell type , Yeast, ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.531 12/2001 , ... , , , , ... , Cell type , Yeast, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.527 04/2002 , , , ... , Microorganism , Propionibacterium ... type , Bacteria, gram positive, , ...
Cached Biology Technology:Saccharomyces cerevisiae 2Saccharomyces cerevisiae 2Propionibacterium freudenreichii 2
(Date:4/17/2014)... is available in German . ... recognise objects; they also provide us with a continuous stream ... around, fall or sit still in a car the ... on our retinas. Seemingly without effort, our brain calculates self-motion ... stable position and a steady gaze during our own movements. ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... 8, 2012) A transcription factor called Lyl-1 is necessary ... critical cells born in the thymus that coordinate the immune ... led by those from Baylor College of Medicine (www.bcm.edu) in ... progenitors (called early T lineage progenitor cells) are the first ...
... Zebrafish, popular as aquarium fish, now have an important ... studying human diseases. At the 2012 International Zebrafish ... presentations highlighted the utility of the zebrafish for examining ... potential treatment approaches for an impressive array of organ ...
... from surgery or battle wounds, ugly scars can affect body and ... FASEB Journal offers a new strategy to reduce ... describe how agents that block receptors for adenosine (a molecule generated ... to muscles) can be applied topically to healing wounds to reduce ...
Cached Biology News:Transcription factor Lyl-1 critical in producing early T-cell progenitors 2Zebrafish provide insights into causes and treatment of human diseases 2Zebrafish provide insights into causes and treatment of human diseases 3Zebrafish provide insights into causes and treatment of human diseases 4New York University scientists discover possible treatment to reduce scarring 2
... IS System is ideal for developing single ... This system contains the new, improved, and ... The user can design specific templates for ... has fully integrated graphing and data regression ...
... Sweep- based acquision and analysis ... response type applications. Contains powerful ... flexible analysis functions including automated ... plotting. Also includes many electrophysiology ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: